Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cediranib and/or olaparib versus paclitaxel for advanced endometrial cancer
ISRCTN16320634Phase 2Completed
- Sponsor
- The University of Manchester
- Start
- Feb 2018
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of cediranib, olaparib and paclitaxel in endometrial cancer (EC) and endometrial carcinosarcoma, sponsored by The University of Manchester. Primary endpoint: Progression-free at 3 months. Started Feb 2018; status: completed.
02
Drugs
cediranibolaparibpaclitaxel
03
Conditions
endometrial cancer (EC)endometrial carcinosarcoma
Beyond the preview
Go deeper on ISRCTN16320634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN16320634.